Bioequivalence evaluation of lomefloxacin 400 mg tablets (Lomax® versus Maxaquin®) in healthy human volunteers

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 9, 1999, Pages 407-410

  Al Rashood, Khalid A ^a   Al Khamis, Khalil I ^a   El Sayed, Yoursy M ^a   Al Bella, Sulaiman ^a   Al Yamani, Mohd A ^a   Mahmood Alam, S ^b   Dham, Ruwayda ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Gulf Pharmaceutical Industries   (United Arab Emirates)

Author keywords

Bioequivalence evaluation; Lomefloxacin; Pharmacokinetic parameters

Indexed keywords

LOMAX; LOMEFLOXACIN;

ADULT; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

EID: 0033857315     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-081X(199912)20:9<407::AID-BDD199>3.0.CO;2-F     Document Type: Article

References (18)

1. In-vitro and in-vivo activity of NY-198 a new difluronated quinolone
2. In-vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents
3. In-vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials
4. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses
5. Pharmacokinetics of lomefloxacin in healthy volunteers, comparison of 400 mg once daily and 200 mg twice daily orally for 5 days
6. Pharmacokinetics and tissue penetration of orally administered lomefloxacin
7. Pharmacokinetics and safety of lomefloxacin following multiple doses
8. Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function
9. Pharmacokinetics of lomefloxacin in normal and impaired renal function
10. Dispositioned metabolism of NY-198V, metabolism of 14C NY-198 in rats anddogs
11. The accurate, sensitive and reproducible method for the quantitation of pefloxacin in plasma
12. Use of confidence intervals in analysis of comparative bioavailability trials
13. Comparison of different methods of decision making in bioequivalence assessment
14. An exact confidence interval from untransformed data for the ratio of two formulation mean
15. A comparison of two one-sided tests procedures and the power approach for assessing the bioequivalence of average bioavailability